Skip to main content

Share story

AI Infrastructure

Positron IDE becomes available in Amazon SageMaker AI

Positron IDE becomes available in Amazon SageMaker AI Image: Primary
Posit's Positron development environment now runs as a custom image in Amazon SageMaker AI, giving data scientists one browser-based workspace for R, Python, governed AWS data access, model deployment and reporting. Administrators build Posit's image definition, store it in their own Amazon ECR repository and attach it to a SageMaker Studio domain. Workloads inherit the Studio Space execution role, removing the need to store separate AWS keys. Posit Assistant can also use Amazon Bedrock models in the customer's account and region. Adoption requires a Posit license, administrative configuration and customer-managed security, networking, updates and operational controls.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Artificial Intelligence and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Security Infrastructure
Security Infrastructure

Ransomware attack halts trading on Nepal Stock Exchange

The Nepal Stock Exchange suspended all Monday trading after ransomware hit infrastructure hosting the trading systems of 72 brokerages. Data Hub detected the attack early that morning and kept affected systems offline while invest...

AI Products
AI Products

Tech groups use residual-value guarantees to lower AI financing costs

Large technology companies are increasingly using residual-value guarantees to finance AI equipment off their balance sheets, the Financial Times reports. The guarantees apply the companies' credit strength to the hardware's futur...

Capital Products
Capital Products

Novadip raises €10.4 million to complete pivotal bone-graft trial

Belgian regenerative-medicine company Novadip Biosciences has closed a €10.4 million convertible financing led by New Science Ventures. The funding will support completion of an ongoing Phase 3 trial in the United States and Europ...